For the purpose of broadening and strengthening our drug development capabilities, Formosa Pharma entered strategic alliance agreements with several international biotech companies such as Eyenovia Inc. (USA), AimMax Therapeutics (USA), and EirGenix (Taiwan), and academic collaborators at Taipei Medical University, collaborated with their experienced professionals in pre-clinical translation, clinical trial design, and strategies for global development and commercialization to advance the developments for each assets.

We are aggressively seeking additional valued partnerships to complement our existing pipeline and platform technologies.